M&A Deal Summary |
|
|---|---|
| Date | 2018-11-20 |
| Target | Avista Pharma Solutions |
| Sector | Life Science |
| Buyer(s) | Cambrex |
| Sellers(s) | Ampersand Capital Partners |
| Deal Type | Add-on Acquisition |
| Deal Value | 252M USD |
| Advisor(s) | Goodwin Procter (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1981 |
| Sector | Life Science |
| Employees | 1,228 |
| Revenue | 534M USD (2017) |
Cambrex is a life sciences company that provides products, services, and technologies to accelerate the development and commercialization of small molecule therapeutics. Cambrex was formed in 1981 and is headquartered in East Rutherford, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 5 of 7 |
| Sector (Life Science) | 4 of 5 |
| Type (Add-on Acquisition) | 4 of 6 |
| State (Colorado) | 1 of 1 |
| Country (United States) | 3 of 4 |
| Year (2018) | 2 of 2 |
| Size (of disclosed) | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-07-23 |
Cambrex Drug Product- Business Unit
Whippany, New Jersey, United States Cambrex Drug Product's Business Unit is a technology-focused contract manufacturing business with differentiated applications and capabilities in solid, semi-solid and liquid dosage forms, with a particular focus on controlled substances. Cambrex Drug Product's Business Unit was established in 2006 and is based in Whippany, New Jersey. |
Buy | $425M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-06-01 |
Q1 Scientific
Waterford, Ireland Q1 Scientific is a provider of environmentally-controlled cGMP stability storage services for the pharmaceutical, medical device, and life science industries. Q1 Scientific was founded in 2013 and is based in Waterford, Ireland. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1988 |
| PE ASSETS | 2.0B USD |
| Size | Large |
| Type | Sector Focused |
Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 39 of 53 |
| Sector (Life Science) | 16 of 24 |
| Type (Add-on Acquisition) | 28 of 38 |
| State (Colorado) | 1 of 1 |
| Country (United States) | 39 of 50 |
| Year (2018) | 6 of 6 |
| Size (of disclosed) | 7 of 13 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-10-23 |
Genoptix
Carlsbad, California, United States Genoptix, Inc. is one of the largest hematopathology testing laboratories in the U.S., providing thousands of oncologists and pathologists across the United States with comprehensive testing solutions in hematology and solid tumor molecular profiling. Genoptix, Inc. was founded in 1999 and is based in Carlsbad, California. |
Sell | $126M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-03-24 |
Brammer Bio
Cambridge, Massachusetts, United States Brammer Biopharmaceuticals LLC was founded early in 2015 to create a best-in-class cell and gene therapy contract development and manufacturing organization (CDMO) to enable large pharma and biotech clients to accelerate the delivery of novel medicines to improve patient health. With the in-depth biologics manufacturing knowledge and expertise of founders Mark Bamforth (CEO) and Steven Kasok (CFO), previously cofounders of Gallus Biopharmaceuticals, now as Brammer Bio, the company is positioned to accelerate the development of these important emerging technologies. |
Sell | $1.7B |
